Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED

seekingalpha08-18

Eisai Pharma collaborates with SEED to develop molecular glues for targeted protein degradation, with SEED eligible for up to $1.5 billion in milestones.Shanghai OcuMension acquires Chinese rights to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2460713409?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg","is_english":true,"pubTime":"2024-08-18 19:49","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2460713409","market":"sh","top_or_hot":-1,"title":"Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED","media":"seekingalpha","content":"<div>\n<p>Eisai Pharma collaborates with SEED to develop molecular glues for targeted protein degradation, with SEED eligible for up to $1.5 billion in milestones.Shanghai OcuMension acquires Chinese rights to ...</p>\n\n<a href=\"https://seekingalpha.com/article/4715440-week-review-eisai-enters-1-5-billion-molecular-glues-pact-seed\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeek In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-18 19:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4715440-week-review-eisai-enters-1-5-billion-molecular-glues-pact-seed><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eisai Pharma collaborates with SEED to develop molecular glues for targeted protein degradation, with SEED eligible for up to $1.5 billion in milestones.Shanghai OcuMension acquires Chinese rights to ...</p>\n\n<a href=\"https://seekingalpha.com/article/4715440-week-review-eisai-enters-1-5-billion-molecular-glues-pact-seed\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛欧洲核心股票组合Acc","start_time":0,"source_url":"https://seekingalpha.com/article/4715440-week-review-eisai-enters-1-5-billion-molecular-glues-pact-seed","article_id":"2460713409","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460713409","pubTimestamp":1723981740,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Eisai Pharma collaborates with SEED to develop molecular glues for targeted protein degradation, with SEED eligible for up to $1.5 billion in milestones.Shanghai OcuMension acquires Chinese rights to ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1829250122.USD":"高盛欧洲核心股票组合Acc","ESAIY":"Eisai Co., Ltd.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","BK4198":"医疗保健用品","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ESALF":"Eisai Co., Ltd.","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","MKGAF":"Merck KGaA","ASND":"Ascendis Pharma A/S","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","AZN":"阿斯利康","ASPHF":"ASCENTAGE PHARMA GROUP","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4189":"农产品","ALC":"爱尔康","BK4139":"生物科技","SEED":"奥瑞金种业","BK4007":"制药"},"translate_title":"一周回顾：卫材与SEED签订价值15亿美元的分子胶协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1,"SEED":1,"MKGAF":1,"ESALF":1,"ESAIY":1,"ALC":1,"ASPHF":1,"AZN":1},"content_text":"Eisai Pharma collaborates with SEED to develop molecular glues for targeted protein degradation, with SEED eligible for up to $1.5 billion in milestones.Shanghai OcuMension acquires Chinese rights to a portfolio of dry eye treatments from Alcon in exchange for a 16.7% stake.TYK Medicines stages a Hong Kong IPO to raise $74 million for its portfolio of small molecule cancer drugs, including TY-9591 for lung cancer.   Trevor Williams Deals and Financings Japan’s Eisai Pharma (OTCPK:ESALF)(OTCPK:ESAIY) formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins (see story). SEED is eligible to receive up to $1.5 billion in milestones plus royalties. SEED will lead the preclinical discovery for specified targets, some of them neurological. Eisai will have exclusive rights to develop and commercialize compounds derived from this collaboration. Eisai is also leading a Series A-3 financing for SEED with a first close of $24 million from investors. A second closing of unspecified size will take place later this year. Shanghai OcuMension acquired Chinese rights to a portfolio of dry eye treatments from Alcon (ALC) in exchange for a 16.7% stake in OcuMension’s shares (see story). The shares, which are worth about US$110 million, will make Alcon one of OcuMension’s largest shareholders. Each company will also grant the other company a right of first negotiation over future products. OcuMension is an ophthalmic pharmaceutical company with a portfolio of 25 pharmaceutical assets. Alcon is a global company focused on offering eye care products. TYK Medicines is staging a Hong Kong IPO that will raise US$74 million to support its portfolio of small molecule cancer drugs (see story). TYK is developing 11 drug candidates (including its core product TY-9591), six clinical-stage products and four preclinical or early-stage clinical development products. One year ago, TY-9591 started a pivotal Phase II trial as a first-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases. TY-9591 was designed to improve the efficacy of AstraZeneca’s (AZN) Tagrisso (osimertinib), and it will be compared to osimertinib in the trial. TYK Medicines is headquartered in Huzhou, Zhejiang province, China. Proto Axiom, an Australian biomedical incubator, announced a $20 million first close of a Series B round that is expected to raise $30 million eventually (see story). Proto Axiom describes itself as a holistic enterprise that offers technical oversight, administrative support, future financing and hands-on research assistance. It aims to develop Australian biopharma technology from its Sydney base. With the first closing of the Series B and the $15 million Series A, Proto Axiom has a valuation of $90 million. The Life Science business of Merck KGaA (OTCPK:MKGAF)(MKGAY) Singapore partnered with NSG BioLabs, a Singapore provider of biotech co-working laboratory and office space, to provide resources to biotech start-ups and improve the R&D capabilities of the site’s tenants (see story). The collaboration plans to offer guidance, mentorship, and access to expertise to startups. Since 2019, NSG BioLabs has housed innovators who are developing products for precision medicine, nucleic acids, AI-enabled drug discovery and synthetic biology. NSG BioLabs claims to have helped over 40 companies, including several multi-billion-dollar multinationals, which have raised nearly $400 million. Trials and Approvals Shanghai Visen Pharmaceuticals reported positive data from a China Phase III trial of its hypoparathyroidism therapy (see story). In the 26-week trial, 77.6% of patients treated with palopegteriparatide, a parathyroid, met the primary endpoint compared to none in the placebo. Palopegteriparatide (TransCon PTH) is an investigational prodrug of PTH (1-34), administered once daily. Its sustained release of active PTH is designed to provide PTH levels in the physiological range for 24 hours/day. Visen, a biopharma focused on endocrine diseases, acquired China rights to the drug from Ascendis Pharma (ASND) of Copenhagen. Suzhou Ascentage Pharma (OTCPK:ASPHF) has been cleared to start China Phase III trials of lisaftoclax (APG-2575) as a first-line treatment of newly-diagnosed patients with higher-risk myelodysplastic syndrome (MDS) (see story). Lisaftoclax will be administered in combination with azacitidine (AZA). Lisaftoclax is a novel, oral Bcl-2 selective inhibitor that is designed to block the antiapoptotic protein Bcl-2, restoring the normal apoptosis process in cancer cells. The approval is the fourth Phase III trial for the candidate in China. Biosyngen, a Singapore-Guangzhou cell therapy company, has been approved to start a pivotal US Phase II trial of its Epstein-Barr-Virus-specific CAR-T cell therapy (see story). The trial will enroll patients with relapsed/metastatic EBV-positive nasopharyngeal carcinoma. Biosyngen said BRG01 will be the first cell therapy to begin Phase II trials in both the US and China for the indication. BRG01 is also unusual because it is a cell therapy that targets a solid tumor. Patients were enrolled in a Phase I trial in the US and China earlier this year, and they have received a single BRG01 infusion. Hangzhou Vimgreen Pharma has enrolled 150 Parkinson’s Disease patients in a China Phase II trial of VG081821AC, a novel adenosine A2A receptor (A2AR) antagonist (see story). The candidate also functions as an inverse A2AR agonist. 150 participants with early-to-mid stage Parkinson's disease were randomized into one of three cohorts: high-dose, low-dose and placebo at a ratio of 1:1:1. Vimgreen develops drugs that are based on the modulation of adenosine signaling. Most Parkinson’s therapies use dopamine to treat the symptoms of disease, but Vimgreen’s candidate aims to avoid, decrease or delay motor complications in early-stage PD. Disclosure: none. Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.  Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460713409"}